Related Experiment Video

Updated: May 28, 2026

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle
09:40

Phosphorus-31 Magnetic Resonance Spectroscopy: A Tool for Measuring In Vivo Mitochondrial Oxidative Phosphorylation Capacity in Human Skeletal Muscle

Published on: January 19, 2017

Metabolic syndrome in pediatrics: old concepts revised, new concepts discussed

Ebe D'Adamo1, Nicola Santoro, Sonia Caprio

  • 1Department of Pediatrics, Yale University School of Medicine, PO Box 208064, New Haven, CT 6520, USA.

Pediatric Clinics of North America
|October 11, 2011
PubMed

Insights

Childhood obesity is driving metabolic syndrome and insulin resistance in children. This article explores the causes of metabolic syndrome and obesity's role in pediatric cases.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Disorders
  • Public Health

Background:

  • The global rise in childhood obesity has led to an increase in pediatric metabolic syndrome.
  • Metabolic syndrome in children shares characteristics with adult-onset conditions.
  • Insulin resistance is a primary factor in metabolic syndrome development.

Purpose of the Study:

  • To examine the causes of metabolic syndrome in children.
  • To highlight the significant role of obesity in pediatric metabolic syndrome.
  • To discuss the epidemiological link between obesity and metabolic syndrome prevalence.

Main Methods:

  • Literature review on childhood obesity and metabolic syndrome.
  • Analysis of etiological factors contributing to pediatric metabolic syndrome.
  • Epidemiological data review on obesity and metabolic syndrome trends.

Main Results:

  • Childhood obesity is a major driver of metabolic syndrome in pediatric populations.
  • Insulin resistance, particularly concerning carbohydrate metabolism, is central to the pathogenesis.
  • The prevalence of childhood obesity directly correlates with the incidence of metabolic syndrome.

Conclusions:

  • Obesity is a critical factor in the increasing prevalence of metabolic syndrome among children.
  • Understanding the causes of metabolic syndrome is crucial for pediatric health.
  • Addressing childhood obesity is key to mitigating metabolic syndrome in this age group.

More Related Videos

An Experimental Model of Diet-Induced Metabolic Syndrome in Rabbit: Methodological Considerations, Development, and Assessment10:31

An Experimental Model of Diet-Induced Metabolic Syndrome in Rabbit: Methodological Considerations, Development, and Assessment

Published on: April 20, 2018

Assessment of Child Anthropometry in a Large Epidemiologic Study09:36

Assessment of Child Anthropometry in a Large Epidemiologic Study

Published on: February 2, 2017

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...